Evidence map›Paper›PMID 37938736›Full record

Observational studyBone marrow transplantation2024

Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.

Dawn Maze, Murat O Arcasoy, Ryan Henrie, Sonia Cerquozzi, Rammurti Kamble, Samer Al-Hadidi, Abdulraheem Yacoub, Anurag K Singh, Mahmoud Elsawy, Shireen Sirhan and 11 more

Erratum issuedOpen access · hybridAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 2 countries.

Dawn MazeThe Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. dawn.maze@uhn.ca.ORCID 0000-0002-4598-9380
Murat O ArcasoyDuke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.
Ryan HenrieDivision of Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Sonia CerquozziTom Baker Cancer Centre, Alberta Health Service Calgary Zone, University of Calgary, Calgary, AB, Canada.
Rammurti KambleCenter for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital, Houston, TX, USA.
Samer Al-HadidiMyeloma Section, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Abdulraheem YacoubDivision of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA.
Anurag K SinghDivision of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA.ORCID 0000-0003-1114-9508
Mahmoud ElsawyDivision of Hematology, Dalhousie University, Halifax, NS, Canada.ORCID 0000-0001-9872-2471
Shireen SirhanJewish General Hospital, McGill University, Montreal, QC, Canada.
Elliot SmithThe Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Curtis MarcouxDivision of Hematology, Dalhousie University, Halifax, NS, Canada.
Auro ViswabandyaThe Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-9690-4669
Andrew DalyTom Baker Cancer Centre, Alberta Health Service Calgary Zone, University of Calgary, Calgary, AB, Canada.
Hassan SibaiThe Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Caroline McNamaraThe Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Yuliang ShiDepartment of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Wei XuDepartment of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Katherine LajkoszDepartment of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Lynda FoltzDivision of Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Vikas GuptaThe Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-1419-8607
University of Toronto · CAUniversity Health Network · CAAlberta Health Services · CADalhousie University · CAUniversity of British Columbia · CAUniversity of Kansas Medical Center · USBaylor College of Medicine · USDuke University · USJewish General Hospital · CAWinthrop Rockefeller Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF) and is recommended for patients with higher risk disease. However, there is a risk of early mortality, and optimal timing is unknown. JAK inhibitor (JAKi) therapy may offer durable improvement in symptoms, splenomegaly and quality of life. The aim of this multicentre, retrospective observational study was to compare outcomes of patients aged 70 years or below with MF in chronic phase who received upfront JAKi therapy vs. upfront HCT in dynamic international prognostic scoring system (DIPSS)-stratified categories. For the whole study cohort, median overall survival (OS) was longer for patients who received a JAKi vs. upfront HCT, 69 (95% CI 57-89) vs. 42 (95% CI 20-not reached, NR) months, respectively (p = 0.01). In patients with intermediate-2 and high-risk disease, median OS was 55 (95% CI 36-73) months with JAKi vs. 36 (95% CI 20-NR) months for HCT (p = 0.27). An upfront HCT strategy was associated with early mortality and difference in median OS was not observed in any risk group by 5 years of follow-up. Within the limitations of a retrospective observational study, we did not observe any benefit of a universal upfront HCT approach for higher-risk MF.

Indexed as

Hematopoietic Stem Cell TransplantationJanus Kinase InhibitorsPrimary MyelofibrosisHumansNorth AmericaQuality of LifeRetrospective StudiesTransplantation, HomologousJanus Kinase Inhibitors

Identifiers

PMID37938736
PMCPMC10849956
OpenAlexW4388490413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.